Palomid 529 inhibits mTORC1/2 and exhibits anticancer chemotherapeutic and anti-angiogenic activities. Palomid 529 is currently in clinical trials as a potential treatment for macular degeneration. In mice with BRCA-1-deficient breast cancer tumors, palomid 529 inhibits tumor growth. Palomid 529 also inhibits angiogenesis and vascular permeability in cellular models. Additionally, palomid 529 indirectly inhibits downstream Akt signaling.